Cargando…

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis

OBJECTIVE: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. METHODS: We searched the literature using PubMed, the Cochrane Library, and Web of Science from their inception to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yong, Lu, Xiaoju, Lin, Qimou, Li, Weiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416144/
https://www.ncbi.nlm.nih.gov/pubmed/32762463
http://dx.doi.org/10.1177/0300060520943473
_version_ 1783569270690545664
author Li, Yong
Lu, Xiaoju
Lin, Qimou
Li, Weiwen
author_facet Li, Yong
Lu, Xiaoju
Lin, Qimou
Li, Weiwen
author_sort Li, Yong
collection PubMed
description OBJECTIVE: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. METHODS: We searched the literature using PubMed, the Cochrane Library, and Web of Science from their inception to December 15, 2019 based on predetermined inclusion and exclusion criteria. The relevant studies compared pathologic complete response (pCR) and adverse event rates. RESULTS: The meta-analysis included five studies and 2335 patients. Compared with conventional taxanes, neoadjuvant chemotherapy with nab-paclitaxel was associated with a higher pCR rate (odds ratio [OR] = 1.39, 95% confidence interval [CI] = 1.16–1.67), especially among patients with triple-negative breast cancer or Ki67 indices of >20%. Pooled outcomes also revealed better event-free survival in the nab-paclitaxel group (hazard ratio = 0.69, 95% CI = 0.57–0.85). However, all-grade (OR = 2.17, 95% CI = 1.38–3.40) and grade ≥3 peripheral sensory neuropathy (OR = 3.92, 95% CI = 2.44–6.28) were more frequent in the nab-paclitaxel group. CONCLUSIONS: This meta-analysis implied that nab-paclitaxel more effectively improved pCR than conventional taxanes. Nab-paclitaxel may have greater benefits in patients with triple-negative breast cancer. However, additional attention is required for the early diagnosis and management of peripheral sensory neuropathy.
format Online
Article
Text
id pubmed-7416144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74161442020-08-24 Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis Li, Yong Lu, Xiaoju Lin, Qimou Li, Weiwen J Int Med Res Meta Analysis OBJECTIVE: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. METHODS: We searched the literature using PubMed, the Cochrane Library, and Web of Science from their inception to December 15, 2019 based on predetermined inclusion and exclusion criteria. The relevant studies compared pathologic complete response (pCR) and adverse event rates. RESULTS: The meta-analysis included five studies and 2335 patients. Compared with conventional taxanes, neoadjuvant chemotherapy with nab-paclitaxel was associated with a higher pCR rate (odds ratio [OR] = 1.39, 95% confidence interval [CI] = 1.16–1.67), especially among patients with triple-negative breast cancer or Ki67 indices of >20%. Pooled outcomes also revealed better event-free survival in the nab-paclitaxel group (hazard ratio = 0.69, 95% CI = 0.57–0.85). However, all-grade (OR = 2.17, 95% CI = 1.38–3.40) and grade ≥3 peripheral sensory neuropathy (OR = 3.92, 95% CI = 2.44–6.28) were more frequent in the nab-paclitaxel group. CONCLUSIONS: This meta-analysis implied that nab-paclitaxel more effectively improved pCR than conventional taxanes. Nab-paclitaxel may have greater benefits in patients with triple-negative breast cancer. However, additional attention is required for the early diagnosis and management of peripheral sensory neuropathy. SAGE Publications 2020-08-07 /pmc/articles/PMC7416144/ /pubmed/32762463 http://dx.doi.org/10.1177/0300060520943473 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meta Analysis
Li, Yong
Lu, Xiaoju
Lin, Qimou
Li, Weiwen
Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title_full Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title_fullStr Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title_full_unstemmed Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title_short Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
title_sort is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? a meta-analysis
topic Meta Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416144/
https://www.ncbi.nlm.nih.gov/pubmed/32762463
http://dx.doi.org/10.1177/0300060520943473
work_keys_str_mv AT liyong isnabpaclitaxelbetterthanconventionaltaxanesasneoadjuvanttherapyforbreastcancerametaanalysis
AT luxiaoju isnabpaclitaxelbetterthanconventionaltaxanesasneoadjuvanttherapyforbreastcancerametaanalysis
AT linqimou isnabpaclitaxelbetterthanconventionaltaxanesasneoadjuvanttherapyforbreastcancerametaanalysis
AT liweiwen isnabpaclitaxelbetterthanconventionaltaxanesasneoadjuvanttherapyforbreastcancerametaanalysis